Early PsychosisNCT06032182
PSYCHE Cognitive Remediation & Social Recovery Study
A study testing CRESTR Intervention in people with Early Psychosis, run by National University of Ireland, Galway, Ireland at 5 sites in Ireland.
Trial summary
This study is a pilot feasibility study embedded in the Early Intervention in Psychosis (EIP) services in Ireland. It explores the feasibility and acceptability of a combined cognitive remediation training and social recovery therapy intervention. Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Early Psychosis
- What is being tested?
- CRESTR Intervention
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 5 sitesIreland
- Study dates
- 1 Mar 2023to Dec 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Aged between 18 and 60 years of age
- Within the first 5 years of a diagnosed psychotic disorder
- Community based and clinically stable
- Ability to give informed consent
Who cannot join
- History of organic impairment
- IQ< 70
- History of head injury with loss of consciousness > 5-minute duration
Trial locations and contacts
5 sites in 1 country.
5 sites in 1 country
Ireland5 sites, 5 recruiting
- Recruiting
HSE Early Intervention in Psychosis Service, Cork
Cork
Dr Karen O'Connor, 0035321 4233164, karen.oconnor3@hse.ie
- Recruiting
DETECT Early Intervention in Psychosis Service
Dublin
Mary Clarke, Prof.
- Recruiting
Adult Mental Health Service, University Hospital Galway
Galway
Dr Brian Hallahan, 0035391524222 ext. 4162, brian.hallahan@universityofgalway.ie
- Recruiting
HSE Early Intervention in Psychosis Service, Meath
Navan
Dr Marie Whitty, marie.whitty@hse.ie
- Recruiting
HSE Early Intervention in Psychosis Service, Sligo
Sligo
Dr Donagh O'Neil, donagh.oneill@hse.ie
About this study
Official title: PSYCHE Cognitive Remediation & Social Recovery in Early Psychosis Study
This study is a pilot feasibility study embedded in the Early Intervention in Psychosis (EIP) services in Ireland. It explores the feasibility and acceptability of a combined cognitive remediation training and social recovery therapy intervention.
Read the detailed description
The Cognitive Remediation and Social Recovery in Early Psychosis (CRESTR) study is a feasibility study recruiting participants from the Health Service Executive Early Intervention in Psychosis (EIP) services in Sligo, Meath and Cork and the Adult Mental Heath Service in Galway. This study explores the feasibility and acceptability of a novel, 15-week multicomponent psychosocial intervention which combines cognitive remediation training (CRT) and social recovery therapy (SRT). Primary and secondary outcome measures are described later in this registration. The intervention components include:
Component 1: The CRT programme used in this study is the Computerised Interactive Remediation of Cognition- Training for Schizophrenia (CIRCuiTS). CIRCuiTS is a web-based CRT programme which targets metacognition, specifically strategy use, in addition to massed practice of cognitive functions (attention, memory and executive functioning). Collaborative goal setting related to real-world tasks are integral to the programme with the programme tasks and exercises increasing in difficulty in response to the participant's performance and progress. This will be the primary focus of 1:1 therapy for the first 7 weeks with remote practice sessions occurring between therapy visits. After 7 weeks remote practice will continue and the focus of in-person therapy sessions will bridge to social recovery therapy as detailed below.
Component 2: Social recovery therapy (SRT) focuses on addressing barriers to individuals interacting in their social environment e.g., social anxiety. It is informed by cognitive behavioural theory and addresses individual goals. SRT follows an established protocol. In summary, this consists of therapy delivered in three stages. Stage one will include engagement and formulation with the purpose of identifying a problem list and establishing a therapeutic relationship. Stage two will include preparing for new activities with identification of pathways to activity and collaboration with community stakeholders. Stage three will include engagement in new activities using behavioural experiments to promote social activity. This is the primary focus of in-person therapy sessions from week 8 to 15 alongside remote practice of the CRT programme.
- Conditions
- Early Psychosis
- Being tested
- CRESTR Intervention, CRESTR Control
- Keywords
- Recovery, Cognitive remediation training, Cognitive behavioural therapy, Psychosis
- Medical subject headings
- Psychotic Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CRESTR InterventionBehavioural
15 1-hour sessions of CRT + SRT
CRESTR ControlBehavioural
15 1-hour sessions of SRT alone
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Experimental | 15 sessions of the combined cognitive remediation training and social recovery therapy intervention. Receives: Behavioral: CRESTR Intervention |
| Control | Active comparator | 15 sessions of social recovery therapy alone. Receives: Behavioral: CRESTR Control |
What is being measured
The primary outcome is the main question the study is designed to answer.
Social and Occupational Functioning Assessment Scale
Social and Occupational Functional Assessment Scale (Rybarczyk, 2011) is a global rating of current functioning ranging from 0 to 100, with lower scores representing lower functioning.
Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
Secondary outcomes (17)
The Reading the Mind in the Eyes Task
The Reading the mind in the eyes task is a theory of mind task that measures the capacity to understand mental states of others from expressions in the eye region of the face. Participants view 36 photos and choose the most accurate descriptor word from four choices for the thought/feeling that was portrayed. Scores range from 0 to 36 with higher scores indicating better theory of mind ability.
Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
Emotion Recognition Task
The Emotion Recognition Task from the Cambridge Neuropsychological Test Automated Battery (Cambridge Cognition Ltd.)
Computer-morphed images derived from the facial features of real individuals, each showing a specific emotion, are displayed on the screen, one at a time. Each face is displayed for 200ms and then immediately covered up to prevent residual processing of the image. The participant must select which emotion the face displayed from 6 options (sadness, happiness, fear, anger, disgust or surprise).
The outcome measures for ERT will include number correct, which can be looked at either across individual emotions or across all emotions at once. Higher scores indicate superior emotion recognition ability.
Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
The Bell Lysaker Emotion Recognition Task
The Bell Lysaker Emotion Recognition Task measures recognition of seven emotional states: happiness, sadness, fear, disgust, surprise, anger, or no emotion. Participants identified the emotion shown in 21 videos of a male actor providing dynamic facial, vocal-tonal, and upper-body movement cues. Performance is indexed as the total number of correctly identified emotions (ranging from 0 to 21 i.e. a higher score represents superior emotion recognition ability.
Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
Test of Premorbid Functioning
Test of Premorbid Functioning estimates an individual's pre-morbid cognitive and memory functioning. A revised and updated version of the Wechsler Test of Adult Reading™, TOPF helps predict pre-injury IQ and memory abilities. Total score is derived from the number of correct items, ranges from 0-70 with a higher score indicating superior ability.
Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
The matrix reasoning subtest from the Wechsler Adult Scale of Intelligence 3rd edition (WAIS-III)
The matrix reasoning subtest from the Wechsler Adult Scale of Intelligence 3rd edition (WAIS-III) (Wechsler, 1997) is a brief, reliable measure of cognitive ability for use in clinical, educational and research settings. Matrix reasoning subtest scores range from 0 - 26 with higher scores reflecting better perceptual organization. Once raw scores are derived they are converted to scaled scores adjusted for age.
Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
Letter Number Sequencing Task
The letter-number sequencing task from the Wechsler Memory scale 3rd edition WMS-III assesses working memory. Scores range from 0-21. Higher scores on the WMS-III subtests indicate better memory function. Raw scores are converted to scaled scores adjusted for age.
Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
Metacognitive Awareness Scale, Domain Specific
Meta-Cognitive Awareness Scale - Domain Specific encourages reflection of task strategy processes. This domain-specific scale was first constructed to measure participants' awareness of their own metacognition linked to Raven's Progressive Matrices (SPM). Following discriminatory index and Exploratory Factor Analysis, a 15-item scale was derived. Exploratory Factor Analysis showed five factors: Awareness of Engagement in Self-Monitoring, Awareness of Own Ability, Awareness of Responding Speed/Time, Awareness of Alternative Solutions and Awareness of Requisite Problem-Solving Resources. The total score is the sum of the 15-itm scale with higher scores indicating superior metacognitive awareness.
Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
The Scale for the Assessment of Positive Symptoms and the Scale for the Assessment of Negative Symptoms.
The Scale for the Assessment of Positive Symptoms measures positive symptoms on a 24 item scale, this includes 19 negative symptom item ratings, and 5 global factor ratings. Each item is scored on a six point scale from 0-5. The composite total is the sum of the nineteen item ratings. The SANS global total is the sum of the five global ratings. The higher the score the more symptomology or severity of symptoms.
The Scale for the Assessment of Negative Symptoms measures negative symptoms on a 25 item, 6-point scale from 0-5. Items are listed under the five domains of affective blunting, alogia, avolition/apathy, anhedonia/asociality, and attention. Total (Composite) score is calculated as the sum of SANS items 1-7, 9-12, 14-16, 18-21, and 23-24, while SANS (Global) Summary score was calculated as the sum of SANS items 8, 13, 17, 22, and 25. The higher the score the more symptomology or severity of symptoms.
Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
The Patient Health Questionnaire-9
The Patient Health Questionnaire-9 is a brief tool used to diagnose and measure severity of depression. It is adapted from the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). Scores range from 0 to 27 with higher scores indicating more severe depression.
A total score of 0-4 points equals "normal" or minimal depression. Scoring between 5-9 points indicates mild depression, 10-14 points indicates moderate depression, 15-19 points indicates moderately severe depression, and 20 or more points indicates severe depression.
Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
The Generalised Anxiety Disorder Assessment-7
The Generalised Anxiety Disorder Assessment is a seven-item instrument that is used to measure or assess the severity of generalised anxiety disorder (GAD). Each item asks the individual to rate the severity of his or her symptoms over the past two weeks. Total scores range from 0 to 21with higher scores indicating a higher level of anxiety. Clinical categorisations of anxiety levels are: 0-4 (none), 5-9 (mild), 10-14 (moderate), and 15-21 (severe).
Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
Drug Use Disorders Identification Test
The Drug Use Disorders Identification Test is an 11-item self-administered screening instrument for drug-related problems, giving information on the level of drug intake and selected criteria for substance abuse/harmful use and dependence according to the ICD-10 and DSM-4 diagnostic systems. The minimum total score possible is 0, and the maximum total score possible is 44 (i.e. total score range: 0-44). Higher scores reflect higher drug dependence
Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
Alcohol Use Disorders Identification Test
The Alcohol Use Disorders Identification Test is a 10-item screening tool developed by the World Health Organization (WHO) to assess alcohol consumption, drinking behaviors, and alcohol-related problems. The range of possible scores is from 0 to 40 where 0 indicates an abstainer who has never had any problems from alcohol. A score of 1 to 7 suggests low-risk consumption according to World Health Organization (WHO) guidelines. Scores from 8 to 14 suggest hazardous or harmful alcohol consumption and a score of 15 or more indicates the likelihood of alcohol dependence (moderate-severe alcohol use disorder).
Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
EQ-ED-EL Health Questionnaire
The EQ-5D-5L is a self-assessed, health related, quality of life questionnaire. The scale measures quality of life on a 5-component scale including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each level is rated on scale that describes the degree of problems in that area (i.e. I have no problems walking about, slight problems, moderate problems, severe problems, or unable to walk). This tool also has an overall health scale where the rater selects a number between 1-100 to describe the condition of their health, 100 being the best imaginable.
Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
Global Functioning Scale
The Global Functioning Scale: Role: measures performance and amount of support needed in one's specific role (ie, school, work). Social: measures quantity and quality of peer relationships, level of peer conflict, age-appropriate intimate relationships, and involvement with family members. Scale: 1-10, higher scores indicate better functioning.
Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
MIRECC Global Assessment of Function
The MIRECC Global Assessment of Function measures occupational functioning, social functioning, and symptom severity on 3 subscales. 3 subscales scored from 0 to 100, with higher scores indicating better functioning.
Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
Global Assessment of Function
The Global Assessment of Function scale is a 100-point single-item scale designed to measure the global severity of psychiatric illness on the basis of symptom, social, and occupational functioning combined. The scale is divided into 10 anchor intervals, with descriptions and examples of symptoms and of social and occupational functioning. Higher scores indicate better functioning.
Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
Time Use Survey
The Time Use Survey is a semi-structured interview that enquires about time spent over the past month on work, education, voluntary work, leisure, sports, housework or chores, and child care. Time spent on each of the activities is calculated in terms of the average number of hours per week. The activities are summed to create two scores: constructive economic activity (work, education, voluntary work, housework or chores, and child care) and structured activity (constructive economic activity plus leisure and sports activities). Less than 45 hours of structured activity per week is considered a threshold for being at risk of social disability, less than 30 hours per week is threshold for social disability and indicative of poor social functioning, and less than 15 hours per week is considered to reflect serious social disability.
Measured: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Sep 2023
- Study start1 Mar 2023
- Primary completionJun 2025 (estimated)
- Study completionDec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Early PsychosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National University of Ireland, Galway, Ireland
- Sponsor type
- University, hospital or other
- Collaborators
- Health Service Executive, Ireland, Health Research Board, Ireland
- Responsible party
- Principal investigator, Gary Donohoe, National University of Ireland, Galway, Ireland
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06032182
- Sponsor's protocol ID
- NUIRELAND2
- Status last verified
- Mar 2024
- First submitted
- 30 Aug 2023
- Last updated
- 22 Mar 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The full protocol in addition to datasets and statistical code generated during the current study will be available from the corresponding author on reasonable request.
Study at a glance
From the registry record, last updated by the sponsor on 22 Mar 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- PSYCHE Cognitive Remediation & Social Recovery in Early Psychosis Study
- ClinicalTrials.gov ID
- NCT06032182
- Acronym / sponsor ID
- NUIRELAND2
- Conditions
- Early Psychosis
- Keywords
- Recovery, Cognitive remediation training, Cognitive behavioural therapy, Psychosis
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- National University of Ireland, Galway, IrelandUniversity, hospital or other
- Collaborators
- Health Service Executive, Ireland, Health Research Board, Ireland
- Study start
- 1 Mar 2023 (actual)
- Primary completion
- Jun 2025 (estimated)
- Study completion
- Dec 2025 (estimated)
- First posted
- 11 Sep 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a pilot feasibility study embedded in the Early Intervention in Psychosis (EIP) services in Ireland. It explores the feasibility and acceptability of a combined cognitive remediation training and social recovery therapy intervention.
Detailed description
The Cognitive Remediation and Social Recovery in Early Psychosis (CRESTR) study is a feasibility study recruiting participants from the Health Service Executive Early Intervention in Psychosis (EIP) services in Sligo, Meath and Cork and the Adult Mental Heath Service in Galway. This study explores the feasibility and acceptability of a novel, 15-week multicomponent psychosocial intervention which combines cognitive remediation training (CRT) and social recovery therapy (SRT). Primary and secondary outcome measures are described later in this registration. The intervention components include:
Component 1: The CRT programme used in this study is the Computerised Interactive Remediation of Cognition- Training for Schizophrenia (CIRCuiTS). CIRCuiTS is a web-based CRT programme which targets metacognition, specifically strategy use, in addition to massed practice of cognitive functions (attention, memory and executive functioning). Collaborative goal setting related to real-world tasks are integral to the programme with the programme tasks and exercises increasing in difficulty in response to the participant's performance and progress. This will be the primary focus of 1:1 therapy for the first 7 weeks with remote practice sessions occurring between therapy visits. After 7 weeks remote practice will continue and the focus of in-person therapy sessions will bridge to social recovery therapy as detailed below.
Component 2: Social recovery therapy (SRT) focuses on addressing barriers to individuals interacting in their social environment e.g., social anxiety. It is informed by cognitive behavioural theory and addresses individual goals. SRT follows an established protocol. In summary, this consists of therapy delivered in three stages. Stage one will include engagement and formulation with the purpose of identifying a problem list and establishing a therapeutic relationship. Stage two will include preparing for new activities with identification of pathways to activity and collaboration with community stakeholders. Stage three will include engagement in new activities using behavioural experiments to promote social activity. This is the primary focus of in-person therapy sessions from week 8 to 15 alongside remote practice of the CRT programme.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention | Experimental | Behavioral: CRESTR Intervention15 sessions of the combined cognitive remediation training and social recovery therapy intervention. |
| Control | Active comparator | Behavioral: CRESTR Control15 sessions of social recovery therapy alone. |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Aged between 18 and 60 years of age
- Within the first 5 years of a diagnosed psychotic disorder
- Community based and clinically stable
- Ability to give informed consent
Key exclusion criteria (3 listed)
- History of organic impairment
- IQ< 70
- History of head injury with loss of consciousness > 5-minute duration
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CRESTR Intervention15 1-hour sessions of CRT + SRT | Behavioural | Intervention |
| CRESTR Control15 1-hour sessions of SRT alone | Behavioural | Control |
Primary outcome
Social and Occupational Functioning Assessment Scale
Time frame: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
Social and Occupational Functional Assessment Scale (Rybarczyk, 2011) is a global rating of current functioning ranging from 0 to 100, with lower scores representing lower functioning.
17 secondary outcomes
The Reading the Mind in the Eyes Task
Time frame: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
Emotion Recognition Task
Time frame: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
The Bell Lysaker Emotion Recognition Task
Time frame: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
Test of Premorbid Functioning
Time frame: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
The matrix reasoning subtest from the Wechsler Adult Scale of Intelligence 3rd edition (WAIS-III)
Time frame: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
Letter Number Sequencing Task
Time frame: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
Metacognitive Awareness Scale, Domain Specific
Time frame: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
The Scale for the Assessment of Positive Symptoms and the Scale for the Assessment of Negative Symptoms.
Time frame: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
The Patient Health Questionnaire-9
Time frame: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
The Generalised Anxiety Disorder Assessment-7
Time frame: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
Drug Use Disorders Identification Test
Time frame: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
Alcohol Use Disorders Identification Test
Time frame: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
EQ-ED-EL Health Questionnaire
Time frame: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
Global Functioning Scale
Time frame: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
MIRECC Global Assessment of Function
Time frame: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
Global Assessment of Function
Time frame: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
Time Use Survey
Time frame: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Mar 2024.
- Individual participant dataSharing planned: Yes. The full protocol in addition to datasets and statistical code generated during the current study will be available from the corresponding author on reasonable request.
Related trials for Early Psychosis
Not yet recruitingObservational study
Sleep Monitoring for Early Detection of Relapse in People With Schizophrenia or Bipolar Disorder Receiving Usual Treatment
Bipolar Disorder (BD), SCHIZOPHRENIA 1 (Disorder)
Active, not recruiting
Designing and Evaluating a Classroom-Based Mental Health Programme for Adolescents.
Mental Health Promotion
RecruitingObservational study
Sensory Profile and Early Clinical Signs of Calm Room Users
Psychotic Disorders, Personality Disorders
Not yet recruiting
Reducing Stigma - A Treatment for Early Psychosis to Prevent Suicide
Suicide, Mental Health Stigma
Recruiting
On Track for Wellness (OTW) Stepped Wedge Cluster Randomized Trial
Sleep, Physical Activity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing CRESTR Intervention in people with Early Psychosis, run by National University of Ireland, Galway, Ireland at 5 sites in Ireland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 22 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in Ireland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Prof. Gary Donohoe (0035391495122, gary.donohoe@universityofgalway.ie), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Social and Occupational Functioning Assessment Scale (time frame: T0 (Baseline) T1 (1-2 weeks post intervention) T2 (3-month follow up)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Mar 2024.